North East and North Cumbria
ICS Formulary
6 Endocrine system
06-04-04 Gender dysphoria
Buserelin 150microgram Nasal Spray
Suprecur
®
Formulary
150 micrograms per spray; 268 dose spray
Cyproterone Acetate
Formulary
Tablets: 50mg & 100mg
MHRA Drug Safety Update (June 2020): Cyproterone acetate: new advice to minimise risk of meningioma
Estradiol 1mg and 2mg tablets
Formulary
Finasteride 5mg tablets
Formulary
MHRA Drug Safety Update (April 2024): Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment)
Goserelin 3.6mg injection
Formulary
Leuprorelin 11.25mg injection
Formulary
Spironolactone
Formulary
Tablets: 25 mg & 100 mg
Testosterone 1ml injection
Sustanon
®
250
Formulary
Sustanon® 250 1ml injection contains testosterone propionate 30mg, testosterone phenylpropionate 60mg, testosterone isocaproate 60mg and testosterone decanoate 100mg.
Testosterone Gel
Formulary
23 mg/1.15 g (23 mg per actuation); 85.5 g (Testavan
®
)
50 mg/5 g (50 mg per tube); 30 tubes (Testim
®
)
16.2 mg/g (20.25 mg per actuation); 88 g (Testogel
®
)
50 mg/5 g sachet; 30 sachets (Testogel
®
)
20 mg/g (10 mg per actuation); 60 g (Tostran
®
)
Testosterone undecanoate 1gram in 4ml oily injection
Formulary
1g in 4 mL (250 mg/ml oily injection)
Triptorelin Injection
Formulary
3 mg, 3.75 mg, 11.25 mg and 22.5 mg
Links
MHRA Drug Safety Update (April 2024): Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment)
MHRA Drug Safety Update (June 2020): Cyproterone acetate: new advice to minimise risk of meningioma
Northern Region Gender Dysphoria Service - General Guidelines For The Use Of Hormone Treatment In Gender Dysphoria
NTAG Endocrine System Recommendations
Key
Full Site